nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoprolol—CYP2D6—breast cancer	0.195	0.583	CbGaD
Metoprolol—ABCB1—breast cancer	0.139	0.417	CbGaD
Metoprolol—ABCB1—Toremifene—breast cancer	0.0426	0.115	CbGbCtD
Metoprolol—SLC22A2—Vinblastine—breast cancer	0.0399	0.108	CbGbCtD
Metoprolol—CYP2C19—Lapatinib—breast cancer	0.0385	0.104	CbGbCtD
Metoprolol—CYP2D6—Idarubicin—breast cancer	0.0332	0.09	CbGbCtD
Metoprolol—ABCB1—Lapatinib—breast cancer	0.0311	0.0841	CbGbCtD
Metoprolol—CYP2C19—Tamoxifen—breast cancer	0.0193	0.0522	CbGbCtD
Metoprolol—ABCB1—Vinorelbine—breast cancer	0.0172	0.0467	CbGbCtD
Metoprolol—CYP2D6—Vinorelbine—breast cancer	0.0162	0.044	CbGbCtD
Metoprolol—ABCB1—Tamoxifen—breast cancer	0.0155	0.0421	CbGbCtD
Metoprolol—ABCB1—Mitoxantrone—breast cancer	0.0152	0.0411	CbGbCtD
Metoprolol—CYP2D6—Tamoxifen—breast cancer	0.0147	0.0397	CbGbCtD
Metoprolol—ABCB1—Gemcitabine—breast cancer	0.0134	0.0363	CbGbCtD
Metoprolol—ABCB1—Paclitaxel—breast cancer	0.0121	0.0328	CbGbCtD
Metoprolol—ABCB1—Irinotecan—breast cancer	0.0119	0.0323	CbGbCtD
Metoprolol—ABCB1—Vinblastine—breast cancer	0.0106	0.0288	CbGbCtD
Metoprolol—CYP2D6—Vinblastine—breast cancer	0.01	0.0271	CbGbCtD
Metoprolol—ABCB1—Docetaxel—breast cancer	0.00875	0.0237	CbGbCtD
Metoprolol—ABCB1—Doxorubicin—breast cancer	0.00652	0.0177	CbGbCtD
Metoprolol—ABCB1—Methotrexate—breast cancer	0.00632	0.0171	CbGbCtD
Metoprolol—CYP2D6—Doxorubicin—breast cancer	0.00615	0.0166	CbGbCtD
Metoprolol—Chlorphenesin—CYP19A1—breast cancer	0.000421	0.126	CrCbGaD
Metoprolol—Chlorphenesin—BCHE—breast cancer	0.00042	0.126	CrCbGaD
Metoprolol—Betaxolol—CYP2D6—breast cancer	0.000232	0.0697	CrCbGaD
Metoprolol—Bisoprolol—CYP2D6—breast cancer	0.000224	0.0673	CrCbGaD
Metoprolol—Acebutolol—CYP2D6—breast cancer	0.000213	0.0637	CrCbGaD
Metoprolol—Oxprenolol—CYP2D6—breast cancer	0.000211	0.0633	CrCbGaD
Metoprolol—Chlorphenesin—CYP3A4—breast cancer	0.000198	0.0592	CrCbGaD
Metoprolol—Chlorphenesin—PTGS2—breast cancer	0.000193	0.058	CrCbGaD
Metoprolol—Alprenolol—CYP2D6—breast cancer	0.000193	0.0579	CrCbGaD
Metoprolol—Bisoprolol—CYP3A4—breast cancer	0.000192	0.0577	CrCbGaD
Metoprolol—Pindolol—CYP2D6—breast cancer	0.000166	0.0498	CrCbGaD
Metoprolol—Atenolol—ABCB1—breast cancer	0.000164	0.0493	CrCbGaD
Metoprolol—Acebutolol—ABCB1—breast cancer	0.000152	0.0455	CrCbGaD
Metoprolol—Propranolol—CYP1A1—breast cancer	0.000122	0.0365	CrCbGaD
Metoprolol—Propranolol—CYP2D6—breast cancer	9.06e-05	0.0272	CrCbGaD
Metoprolol—Propranolol—CYP3A4—breast cancer	7.77e-05	0.0233	CrCbGaD
Metoprolol—Propranolol—ABCB1—breast cancer	6.47e-05	0.0194	CrCbGaD
Metoprolol—Angiopathy—Methotrexate—breast cancer	5.13e-05	0.000229	CcSEcCtD
Metoprolol—Vomiting—Irinotecan—breast cancer	5.12e-05	0.000229	CcSEcCtD
Metoprolol—Vomiting—Mitoxantrone—breast cancer	5.12e-05	0.000229	CcSEcCtD
Metoprolol—Immune system disorder—Methotrexate—breast cancer	5.1e-05	0.000228	CcSEcCtD
Metoprolol—Dizziness—Fluorouracil—breast cancer	5.1e-05	0.000228	CcSEcCtD
Metoprolol—Visual impairment—Epirubicin—breast cancer	5.1e-05	0.000227	CcSEcCtD
Metoprolol—Mediastinal disorder—Methotrexate—breast cancer	5.09e-05	0.000227	CcSEcCtD
Metoprolol—Agranulocytosis—Doxorubicin—breast cancer	5.09e-05	0.000227	CcSEcCtD
Metoprolol—Rash—Irinotecan—breast cancer	5.08e-05	0.000227	CcSEcCtD
Metoprolol—Rash—Mitoxantrone—breast cancer	5.08e-05	0.000227	CcSEcCtD
Metoprolol—Dermatitis—Irinotecan—breast cancer	5.07e-05	0.000227	CcSEcCtD
Metoprolol—Dermatitis—Mitoxantrone—breast cancer	5.07e-05	0.000227	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Docetaxel—breast cancer	5.07e-05	0.000226	CcSEcCtD
Metoprolol—Headache—Mitoxantrone—breast cancer	5.05e-05	0.000225	CcSEcCtD
Metoprolol—Headache—Irinotecan—breast cancer	5.05e-05	0.000225	CcSEcCtD
Metoprolol—Hypotension—Capecitabine—breast cancer	5.04e-05	0.000225	CcSEcCtD
Metoprolol—Insomnia—Docetaxel—breast cancer	5.04e-05	0.000225	CcSEcCtD
Metoprolol—Paraesthesia—Docetaxel—breast cancer	5e-05	0.000223	CcSEcCtD
Metoprolol—Alopecia—Methotrexate—breast cancer	4.99e-05	0.000223	CcSEcCtD
Metoprolol—Vomiting—Gemcitabine—breast cancer	4.99e-05	0.000223	CcSEcCtD
Metoprolol—Bradycardia—Doxorubicin—breast cancer	4.98e-05	0.000222	CcSEcCtD
Metoprolol—Dyspnoea—Docetaxel—breast cancer	4.96e-05	0.000222	CcSEcCtD
Metoprolol—Somnolence—Docetaxel—breast cancer	4.95e-05	0.000221	CcSEcCtD
Metoprolol—Mental disorder—Methotrexate—breast cancer	4.95e-05	0.000221	CcSEcCtD
Metoprolol—Rash—Gemcitabine—breast cancer	4.95e-05	0.000221	CcSEcCtD
Metoprolol—Dermatitis—Gemcitabine—breast cancer	4.94e-05	0.000221	CcSEcCtD
Metoprolol—Eye disorder—Epirubicin—breast cancer	4.94e-05	0.000221	CcSEcCtD
Metoprolol—Tinnitus—Epirubicin—breast cancer	4.93e-05	0.00022	CcSEcCtD
Metoprolol—Headache—Gemcitabine—breast cancer	4.92e-05	0.000219	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Capecitabine—breast cancer	4.91e-05	0.000219	CcSEcCtD
Metoprolol—Cardiac disorder—Epirubicin—breast cancer	4.91e-05	0.000219	CcSEcCtD
Metoprolol—Vomiting—Fluorouracil—breast cancer	4.91e-05	0.000219	CcSEcCtD
Metoprolol—Rhinitis—Doxorubicin—breast cancer	4.9e-05	0.000219	CcSEcCtD
Metoprolol—Dyspepsia—Docetaxel—breast cancer	4.9e-05	0.000219	CcSEcCtD
Metoprolol—Hepatitis—Doxorubicin—breast cancer	4.89e-05	0.000218	CcSEcCtD
Metoprolol—Insomnia—Capecitabine—breast cancer	4.88e-05	0.000218	CcSEcCtD
Metoprolol—Rash—Fluorouracil—breast cancer	4.86e-05	0.000217	CcSEcCtD
Metoprolol—Dermatitis—Fluorouracil—breast cancer	4.86e-05	0.000217	CcSEcCtD
Metoprolol—Paraesthesia—Capecitabine—breast cancer	4.84e-05	0.000216	CcSEcCtD
Metoprolol—Hypersensitivity—Paclitaxel—breast cancer	4.84e-05	0.000216	CcSEcCtD
Metoprolol—Headache—Fluorouracil—breast cancer	4.83e-05	0.000216	CcSEcCtD
Metoprolol—Oedema peripheral—Doxorubicin—breast cancer	4.82e-05	0.000215	CcSEcCtD
Metoprolol—Dysgeusia—Methotrexate—breast cancer	4.82e-05	0.000215	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Docetaxel—breast cancer	4.81e-05	0.000215	CcSEcCtD
Metoprolol—Connective tissue disorder—Doxorubicin—breast cancer	4.81e-05	0.000215	CcSEcCtD
Metoprolol—Dyspnoea—Capecitabine—breast cancer	4.81e-05	0.000215	CcSEcCtD
Metoprolol—Fatigue—Docetaxel—breast cancer	4.8e-05	0.000214	CcSEcCtD
Metoprolol—Angiopathy—Epirubicin—breast cancer	4.8e-05	0.000214	CcSEcCtD
Metoprolol—Nausea—Mitoxantrone—breast cancer	4.79e-05	0.000214	CcSEcCtD
Metoprolol—Nausea—Irinotecan—breast cancer	4.79e-05	0.000214	CcSEcCtD
Metoprolol—Immune system disorder—Epirubicin—breast cancer	4.78e-05	0.000213	CcSEcCtD
Metoprolol—Mediastinal disorder—Epirubicin—breast cancer	4.76e-05	0.000213	CcSEcCtD
Metoprolol—Pain—Docetaxel—breast cancer	4.76e-05	0.000213	CcSEcCtD
Metoprolol—Constipation—Docetaxel—breast cancer	4.76e-05	0.000213	CcSEcCtD
Metoprolol—Dyspepsia—Capecitabine—breast cancer	4.75e-05	0.000212	CcSEcCtD
Metoprolol—Arrhythmia—Epirubicin—breast cancer	4.72e-05	0.000211	CcSEcCtD
Metoprolol—Visual impairment—Doxorubicin—breast cancer	4.71e-05	0.00021	CcSEcCtD
Metoprolol—Asthenia—Paclitaxel—breast cancer	4.71e-05	0.00021	CcSEcCtD
Metoprolol—Alopecia—Epirubicin—breast cancer	4.67e-05	0.000209	CcSEcCtD
Metoprolol—Nausea—Gemcitabine—breast cancer	4.66e-05	0.000208	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Capecitabine—breast cancer	4.65e-05	0.000208	CcSEcCtD
Metoprolol—Fatigue—Capecitabine—breast cancer	4.65e-05	0.000208	CcSEcCtD
Metoprolol—Pruritus—Paclitaxel—breast cancer	4.65e-05	0.000207	CcSEcCtD
Metoprolol—Vision blurred—Methotrexate—breast cancer	4.63e-05	0.000207	CcSEcCtD
Metoprolol—Mental disorder—Epirubicin—breast cancer	4.63e-05	0.000207	CcSEcCtD
Metoprolol—Pain—Capecitabine—breast cancer	4.61e-05	0.000206	CcSEcCtD
Metoprolol—Constipation—Capecitabine—breast cancer	4.61e-05	0.000206	CcSEcCtD
Metoprolol—Feeling abnormal—Docetaxel—breast cancer	4.59e-05	0.000205	CcSEcCtD
Metoprolol—Nausea—Fluorouracil—breast cancer	4.58e-05	0.000205	CcSEcCtD
Metoprolol—Eye disorder—Doxorubicin—breast cancer	4.57e-05	0.000204	CcSEcCtD
Metoprolol—Tinnitus—Doxorubicin—breast cancer	4.56e-05	0.000204	CcSEcCtD
Metoprolol—Gastrointestinal pain—Docetaxel—breast cancer	4.55e-05	0.000203	CcSEcCtD
Metoprolol—Cardiac disorder—Doxorubicin—breast cancer	4.54e-05	0.000203	CcSEcCtD
Metoprolol—Flatulence—Epirubicin—breast cancer	4.54e-05	0.000202	CcSEcCtD
Metoprolol—Tension—Epirubicin—breast cancer	4.52e-05	0.000202	CcSEcCtD
Metoprolol—Dysgeusia—Epirubicin—breast cancer	4.51e-05	0.000201	CcSEcCtD
Metoprolol—Diarrhoea—Paclitaxel—breast cancer	4.5e-05	0.000201	CcSEcCtD
Metoprolol—Nervousness—Epirubicin—breast cancer	4.47e-05	0.0002	CcSEcCtD
Metoprolol—Feeling abnormal—Capecitabine—breast cancer	4.44e-05	0.000198	CcSEcCtD
Metoprolol—Angiopathy—Doxorubicin—breast cancer	4.44e-05	0.000198	CcSEcCtD
Metoprolol—Muscle spasms—Epirubicin—breast cancer	4.42e-05	0.000198	CcSEcCtD
Metoprolol—Immune system disorder—Doxorubicin—breast cancer	4.42e-05	0.000197	CcSEcCtD
Metoprolol—Vertigo—Methotrexate—breast cancer	4.42e-05	0.000197	CcSEcCtD
Metoprolol—Gastrointestinal pain—Capecitabine—breast cancer	4.41e-05	0.000197	CcSEcCtD
Metoprolol—Mediastinal disorder—Doxorubicin—breast cancer	4.41e-05	0.000197	CcSEcCtD
Metoprolol—Body temperature increased—Docetaxel—breast cancer	4.4e-05	0.000197	CcSEcCtD
Metoprolol—Abdominal pain—Docetaxel—breast cancer	4.4e-05	0.000197	CcSEcCtD
Metoprolol—Leukopenia—Methotrexate—breast cancer	4.4e-05	0.000197	CcSEcCtD
Metoprolol—Arrhythmia—Doxorubicin—breast cancer	4.37e-05	0.000195	CcSEcCtD
Metoprolol—Dizziness—Paclitaxel—breast cancer	4.34e-05	0.000194	CcSEcCtD
Metoprolol—Vision blurred—Epirubicin—breast cancer	4.34e-05	0.000194	CcSEcCtD
Metoprolol—Alopecia—Doxorubicin—breast cancer	4.32e-05	0.000193	CcSEcCtD
Metoprolol—Mental disorder—Doxorubicin—breast cancer	4.29e-05	0.000191	CcSEcCtD
Metoprolol—Urticaria—Capecitabine—breast cancer	4.28e-05	0.000191	CcSEcCtD
Metoprolol—Body temperature increased—Capecitabine—breast cancer	4.26e-05	0.00019	CcSEcCtD
Metoprolol—Abdominal pain—Capecitabine—breast cancer	4.26e-05	0.00019	CcSEcCtD
Metoprolol—Flatulence—Doxorubicin—breast cancer	4.2e-05	0.000187	CcSEcCtD
Metoprolol—Arthralgia—Methotrexate—breast cancer	4.19e-05	0.000187	CcSEcCtD
Metoprolol—Chest pain—Methotrexate—breast cancer	4.19e-05	0.000187	CcSEcCtD
Metoprolol—Tension—Doxorubicin—breast cancer	4.18e-05	0.000187	CcSEcCtD
Metoprolol—Vomiting—Paclitaxel—breast cancer	4.18e-05	0.000186	CcSEcCtD
Metoprolol—Dysgeusia—Doxorubicin—breast cancer	4.17e-05	0.000186	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	4.16e-05	0.000186	CcSEcCtD
Metoprolol—Rash—Paclitaxel—breast cancer	4.14e-05	0.000185	CcSEcCtD
Metoprolol—Dermatitis—Paclitaxel—breast cancer	4.14e-05	0.000185	CcSEcCtD
Metoprolol—Nervousness—Doxorubicin—breast cancer	4.14e-05	0.000185	CcSEcCtD
Metoprolol—Vertigo—Epirubicin—breast cancer	4.14e-05	0.000185	CcSEcCtD
Metoprolol—Syncope—Epirubicin—breast cancer	4.13e-05	0.000184	CcSEcCtD
Metoprolol—Leukopenia—Epirubicin—breast cancer	4.12e-05	0.000184	CcSEcCtD
Metoprolol—Headache—Paclitaxel—breast cancer	4.12e-05	0.000184	CcSEcCtD
Metoprolol—Hypersensitivity—Docetaxel—breast cancer	4.1e-05	0.000183	CcSEcCtD
Metoprolol—Muscle spasms—Doxorubicin—breast cancer	4.09e-05	0.000183	CcSEcCtD
Metoprolol—Palpitations—Epirubicin—breast cancer	4.07e-05	0.000182	CcSEcCtD
Metoprolol—Confusional state—Methotrexate—breast cancer	4.05e-05	0.000181	CcSEcCtD
Metoprolol—Loss of consciousness—Epirubicin—breast cancer	4.05e-05	0.000181	CcSEcCtD
Metoprolol—Vision blurred—Doxorubicin—breast cancer	4.01e-05	0.000179	CcSEcCtD
Metoprolol—Asthenia—Docetaxel—breast cancer	4e-05	0.000178	CcSEcCtD
Metoprolol—Hypertension—Epirubicin—breast cancer	3.97e-05	0.000177	CcSEcCtD
Metoprolol—Hypersensitivity—Capecitabine—breast cancer	3.97e-05	0.000177	CcSEcCtD
Metoprolol—Pruritus—Docetaxel—breast cancer	3.94e-05	0.000176	CcSEcCtD
Metoprolol—Nervous system disorder—Methotrexate—breast cancer	3.94e-05	0.000176	CcSEcCtD
Metoprolol—Thrombocytopenia—Methotrexate—breast cancer	3.93e-05	0.000175	CcSEcCtD
Metoprolol—Arthralgia—Epirubicin—breast cancer	3.92e-05	0.000175	CcSEcCtD
Metoprolol—Chest pain—Epirubicin—breast cancer	3.92e-05	0.000175	CcSEcCtD
Metoprolol—Anxiety—Epirubicin—breast cancer	3.9e-05	0.000174	CcSEcCtD
Metoprolol—Nausea—Paclitaxel—breast cancer	3.9e-05	0.000174	CcSEcCtD
Metoprolol—Skin disorder—Methotrexate—breast cancer	3.9e-05	0.000174	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	3.89e-05	0.000174	CcSEcCtD
Metoprolol—Hyperhidrosis—Methotrexate—breast cancer	3.88e-05	0.000173	CcSEcCtD
Metoprolol—Asthenia—Capecitabine—breast cancer	3.87e-05	0.000173	CcSEcCtD
Metoprolol—Dry mouth—Epirubicin—breast cancer	3.83e-05	0.000171	CcSEcCtD
Metoprolol—Vertigo—Doxorubicin—breast cancer	3.83e-05	0.000171	CcSEcCtD
Metoprolol—Syncope—Doxorubicin—breast cancer	3.82e-05	0.00017	CcSEcCtD
Metoprolol—Pruritus—Capecitabine—breast cancer	3.81e-05	0.00017	CcSEcCtD
Metoprolol—Leukopenia—Doxorubicin—breast cancer	3.81e-05	0.00017	CcSEcCtD
Metoprolol—Diarrhoea—Docetaxel—breast cancer	3.81e-05	0.00017	CcSEcCtD
Metoprolol—Confusional state—Epirubicin—breast cancer	3.79e-05	0.000169	CcSEcCtD
Metoprolol—Palpitations—Doxorubicin—breast cancer	3.76e-05	0.000168	CcSEcCtD
Metoprolol—Oedema—Epirubicin—breast cancer	3.76e-05	0.000168	CcSEcCtD
Metoprolol—Hypotension—Methotrexate—breast cancer	3.75e-05	0.000167	CcSEcCtD
Metoprolol—Loss of consciousness—Doxorubicin—breast cancer	3.74e-05	0.000167	CcSEcCtD
Metoprolol—Shock—Epirubicin—breast cancer	3.7e-05	0.000165	CcSEcCtD
Metoprolol—Diarrhoea—Capecitabine—breast cancer	3.69e-05	0.000165	CcSEcCtD
Metoprolol—Nervous system disorder—Epirubicin—breast cancer	3.68e-05	0.000164	CcSEcCtD
Metoprolol—Dizziness—Docetaxel—breast cancer	3.68e-05	0.000164	CcSEcCtD
Metoprolol—Thrombocytopenia—Epirubicin—breast cancer	3.68e-05	0.000164	CcSEcCtD
Metoprolol—Hypertension—Doxorubicin—breast cancer	3.68e-05	0.000164	CcSEcCtD
Metoprolol—Tachycardia—Epirubicin—breast cancer	3.67e-05	0.000164	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Methotrexate—breast cancer	3.66e-05	0.000163	CcSEcCtD
Metoprolol—Skin disorder—Epirubicin—breast cancer	3.65e-05	0.000163	CcSEcCtD
Metoprolol—Hyperhidrosis—Epirubicin—breast cancer	3.63e-05	0.000162	CcSEcCtD
Metoprolol—Insomnia—Methotrexate—breast cancer	3.63e-05	0.000162	CcSEcCtD
Metoprolol—Chest pain—Doxorubicin—breast cancer	3.63e-05	0.000162	CcSEcCtD
Metoprolol—Arthralgia—Doxorubicin—breast cancer	3.63e-05	0.000162	CcSEcCtD
Metoprolol—Anxiety—Doxorubicin—breast cancer	3.61e-05	0.000161	CcSEcCtD
Metoprolol—Paraesthesia—Methotrexate—breast cancer	3.6e-05	0.000161	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.6e-05	0.000161	CcSEcCtD
Metoprolol—Dyspnoea—Methotrexate—breast cancer	3.58e-05	0.00016	CcSEcCtD
Metoprolol—Somnolence—Methotrexate—breast cancer	3.57e-05	0.000159	CcSEcCtD
Metoprolol—Dizziness—Capecitabine—breast cancer	3.57e-05	0.000159	CcSEcCtD
Metoprolol—Dry mouth—Doxorubicin—breast cancer	3.55e-05	0.000158	CcSEcCtD
Metoprolol—Vomiting—Docetaxel—breast cancer	3.54e-05	0.000158	CcSEcCtD
Metoprolol—Dyspepsia—Methotrexate—breast cancer	3.53e-05	0.000158	CcSEcCtD
Metoprolol—Rash—Docetaxel—breast cancer	3.51e-05	0.000157	CcSEcCtD
Metoprolol—Hypotension—Epirubicin—breast cancer	3.51e-05	0.000157	CcSEcCtD
Metoprolol—Dermatitis—Docetaxel—breast cancer	3.51e-05	0.000157	CcSEcCtD
Metoprolol—Confusional state—Doxorubicin—breast cancer	3.5e-05	0.000156	CcSEcCtD
Metoprolol—Headache—Docetaxel—breast cancer	3.49e-05	0.000156	CcSEcCtD
Metoprolol—Oedema—Doxorubicin—breast cancer	3.48e-05	0.000155	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Methotrexate—breast cancer	3.47e-05	0.000155	CcSEcCtD
Metoprolol—Fatigue—Methotrexate—breast cancer	3.46e-05	0.000154	CcSEcCtD
Metoprolol—Pain—Methotrexate—breast cancer	3.43e-05	0.000153	CcSEcCtD
Metoprolol—Vomiting—Capecitabine—breast cancer	3.43e-05	0.000153	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Epirubicin—breast cancer	3.42e-05	0.000153	CcSEcCtD
Metoprolol—Shock—Doxorubicin—breast cancer	3.42e-05	0.000153	CcSEcCtD
Metoprolol—Nervous system disorder—Doxorubicin—breast cancer	3.41e-05	0.000152	CcSEcCtD
Metoprolol—Thrombocytopenia—Doxorubicin—breast cancer	3.4e-05	0.000152	CcSEcCtD
Metoprolol—Rash—Capecitabine—breast cancer	3.4e-05	0.000152	CcSEcCtD
Metoprolol—Insomnia—Epirubicin—breast cancer	3.4e-05	0.000152	CcSEcCtD
Metoprolol—Dermatitis—Capecitabine—breast cancer	3.4e-05	0.000152	CcSEcCtD
Metoprolol—Tachycardia—Doxorubicin—breast cancer	3.39e-05	0.000151	CcSEcCtD
Metoprolol—Headache—Capecitabine—breast cancer	3.38e-05	0.000151	CcSEcCtD
Metoprolol—Skin disorder—Doxorubicin—breast cancer	3.38e-05	0.000151	CcSEcCtD
Metoprolol—Paraesthesia—Epirubicin—breast cancer	3.37e-05	0.000151	CcSEcCtD
Metoprolol—Hyperhidrosis—Doxorubicin—breast cancer	3.36e-05	0.00015	CcSEcCtD
Metoprolol—Dyspnoea—Epirubicin—breast cancer	3.35e-05	0.000149	CcSEcCtD
Metoprolol—Somnolence—Epirubicin—breast cancer	3.34e-05	0.000149	CcSEcCtD
Metoprolol—Nausea—Docetaxel—breast cancer	3.31e-05	0.000148	CcSEcCtD
Metoprolol—Feeling abnormal—Methotrexate—breast cancer	3.31e-05	0.000148	CcSEcCtD
Metoprolol—Dyspepsia—Epirubicin—breast cancer	3.31e-05	0.000148	CcSEcCtD
Metoprolol—Gastrointestinal pain—Methotrexate—breast cancer	3.28e-05	0.000147	CcSEcCtD
Metoprolol—Hypotension—Doxorubicin—breast cancer	3.25e-05	0.000145	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Epirubicin—breast cancer	3.24e-05	0.000145	CcSEcCtD
Metoprolol—Fatigue—Epirubicin—breast cancer	3.24e-05	0.000145	CcSEcCtD
Metoprolol—Pain—Epirubicin—breast cancer	3.21e-05	0.000143	CcSEcCtD
Metoprolol—Constipation—Epirubicin—breast cancer	3.21e-05	0.000143	CcSEcCtD
Metoprolol—Nausea—Capecitabine—breast cancer	3.2e-05	0.000143	CcSEcCtD
Metoprolol—Urticaria—Methotrexate—breast cancer	3.19e-05	0.000142	CcSEcCtD
Metoprolol—Abdominal pain—Methotrexate—breast cancer	3.17e-05	0.000142	CcSEcCtD
Metoprolol—Body temperature increased—Methotrexate—breast cancer	3.17e-05	0.000142	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.17e-05	0.000141	CcSEcCtD
Metoprolol—Insomnia—Doxorubicin—breast cancer	3.14e-05	0.00014	CcSEcCtD
Metoprolol—Paraesthesia—Doxorubicin—breast cancer	3.12e-05	0.000139	CcSEcCtD
Metoprolol—Dyspnoea—Doxorubicin—breast cancer	3.1e-05	0.000138	CcSEcCtD
Metoprolol—Feeling abnormal—Epirubicin—breast cancer	3.1e-05	0.000138	CcSEcCtD
Metoprolol—Somnolence—Doxorubicin—breast cancer	3.09e-05	0.000138	CcSEcCtD
Metoprolol—Gastrointestinal pain—Epirubicin—breast cancer	3.07e-05	0.000137	CcSEcCtD
Metoprolol—Dyspepsia—Doxorubicin—breast cancer	3.06e-05	0.000137	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Doxorubicin—breast cancer	3e-05	0.000134	CcSEcCtD
Metoprolol—Fatigue—Doxorubicin—breast cancer	3e-05	0.000134	CcSEcCtD
Metoprolol—Urticaria—Epirubicin—breast cancer	2.98e-05	0.000133	CcSEcCtD
Metoprolol—Pain—Doxorubicin—breast cancer	2.97e-05	0.000133	CcSEcCtD
Metoprolol—Constipation—Doxorubicin—breast cancer	2.97e-05	0.000133	CcSEcCtD
Metoprolol—Body temperature increased—Epirubicin—breast cancer	2.97e-05	0.000133	CcSEcCtD
Metoprolol—Abdominal pain—Epirubicin—breast cancer	2.97e-05	0.000133	CcSEcCtD
Metoprolol—Hypersensitivity—Methotrexate—breast cancer	2.96e-05	0.000132	CcSEcCtD
Metoprolol—Asthenia—Methotrexate—breast cancer	2.88e-05	0.000129	CcSEcCtD
Metoprolol—Feeling abnormal—Doxorubicin—breast cancer	2.86e-05	0.000128	CcSEcCtD
Metoprolol—Gastrointestinal pain—Doxorubicin—breast cancer	2.84e-05	0.000127	CcSEcCtD
Metoprolol—Pruritus—Methotrexate—breast cancer	2.84e-05	0.000127	CcSEcCtD
Metoprolol—Hypersensitivity—Epirubicin—breast cancer	2.77e-05	0.000124	CcSEcCtD
Metoprolol—Urticaria—Doxorubicin—breast cancer	2.76e-05	0.000123	CcSEcCtD
Metoprolol—Abdominal pain—Doxorubicin—breast cancer	2.75e-05	0.000123	CcSEcCtD
Metoprolol—Body temperature increased—Doxorubicin—breast cancer	2.75e-05	0.000123	CcSEcCtD
Metoprolol—Diarrhoea—Methotrexate—breast cancer	2.75e-05	0.000123	CcSEcCtD
Metoprolol—Asthenia—Epirubicin—breast cancer	2.7e-05	0.00012	CcSEcCtD
Metoprolol—Pruritus—Epirubicin—breast cancer	2.66e-05	0.000119	CcSEcCtD
Metoprolol—Dizziness—Methotrexate—breast cancer	2.65e-05	0.000118	CcSEcCtD
Metoprolol—Diarrhoea—Epirubicin—breast cancer	2.57e-05	0.000115	CcSEcCtD
Metoprolol—Hypersensitivity—Doxorubicin—breast cancer	2.56e-05	0.000114	CcSEcCtD
Metoprolol—Vomiting—Methotrexate—breast cancer	2.55e-05	0.000114	CcSEcCtD
Metoprolol—Rash—Methotrexate—breast cancer	2.53e-05	0.000113	CcSEcCtD
Metoprolol—Dermatitis—Methotrexate—breast cancer	2.53e-05	0.000113	CcSEcCtD
Metoprolol—Headache—Methotrexate—breast cancer	2.51e-05	0.000112	CcSEcCtD
Metoprolol—Asthenia—Doxorubicin—breast cancer	2.49e-05	0.000111	CcSEcCtD
Metoprolol—Dizziness—Epirubicin—breast cancer	2.48e-05	0.000111	CcSEcCtD
Metoprolol—Pruritus—Doxorubicin—breast cancer	2.46e-05	0.00011	CcSEcCtD
Metoprolol—Vomiting—Epirubicin—breast cancer	2.39e-05	0.000107	CcSEcCtD
Metoprolol—Nausea—Methotrexate—breast cancer	2.38e-05	0.000106	CcSEcCtD
Metoprolol—Diarrhoea—Doxorubicin—breast cancer	2.38e-05	0.000106	CcSEcCtD
Metoprolol—Rash—Epirubicin—breast cancer	2.37e-05	0.000106	CcSEcCtD
Metoprolol—Dermatitis—Epirubicin—breast cancer	2.37e-05	0.000106	CcSEcCtD
Metoprolol—Headache—Epirubicin—breast cancer	2.35e-05	0.000105	CcSEcCtD
Metoprolol—Dizziness—Doxorubicin—breast cancer	2.3e-05	0.000103	CcSEcCtD
Metoprolol—Nausea—Epirubicin—breast cancer	2.23e-05	9.96e-05	CcSEcCtD
Metoprolol—Vomiting—Doxorubicin—breast cancer	2.21e-05	9.86e-05	CcSEcCtD
Metoprolol—Rash—Doxorubicin—breast cancer	2.19e-05	9.78e-05	CcSEcCtD
Metoprolol—Dermatitis—Doxorubicin—breast cancer	2.19e-05	9.77e-05	CcSEcCtD
Metoprolol—Headache—Doxorubicin—breast cancer	2.18e-05	9.72e-05	CcSEcCtD
Metoprolol—Nausea—Doxorubicin—breast cancer	2.06e-05	9.22e-05	CcSEcCtD
Metoprolol—ADRB1—Signaling Pathways—FGFR2—breast cancer	7.31e-06	0.000105	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ENO1—breast cancer	7.29e-06	0.000105	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTGS1—breast cancer	7.29e-06	0.000105	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SPP1—breast cancer	7.24e-06	0.000104	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—CXCL8—breast cancer	7.21e-06	0.000104	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NCOA2—breast cancer	7.19e-06	0.000103	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ERBB3—breast cancer	7.17e-06	0.000103	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—FGFR2—breast cancer	7.15e-06	0.000103	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP2D6—breast cancer	7.15e-06	0.000103	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—IL2—breast cancer	7.05e-06	0.000101	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TERT—breast cancer	7.02e-06	0.000101	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NCOA2—breast cancer	7.01e-06	0.000101	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—FASN—breast cancer	6.97e-06	0.0001	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—BCHE—breast cancer	6.94e-06	9.97e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP17A1—breast cancer	6.94e-06	9.96e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—IL2—breast cancer	6.89e-06	9.9e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TERT—breast cancer	6.87e-06	9.86e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTGS1—breast cancer	6.87e-06	9.86e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ENO1—breast cancer	6.87e-06	9.86e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—SLC5A5—breast cancer	6.85e-06	9.85e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—FGFR1—breast cancer	6.82e-06	9.79e-05	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	6.81e-06	9.79e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—FASN—breast cancer	6.8e-06	9.77e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—BCHE—breast cancer	6.77e-06	9.73e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CG—breast cancer	6.73e-06	9.67e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HIF1A—breast cancer	6.71e-06	9.64e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—SLC5A5—breast cancer	6.69e-06	9.61e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—FGFR1—breast cancer	6.67e-06	9.58e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NQO1—breast cancer	6.62e-06	9.51e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—SLC2A1—breast cancer	6.62e-06	9.51e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NCOA2—breast cancer	6.61e-06	9.49e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HIF1A—breast cancer	6.57e-06	9.43e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—LEP—breast cancer	6.55e-06	9.41e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CAV1—breast cancer	6.49e-06	9.33e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	6.48e-06	9.31e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—SLC2A1—breast cancer	6.46e-06	9.28e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NQO1—breast cancer	6.46e-06	9.28e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYP3A4—breast cancer	6.46e-06	9.27e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	6.42e-06	9.23e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KDR—breast cancer	6.42e-06	9.22e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—LEP—breast cancer	6.41e-06	9.21e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—FASN—breast cancer	6.41e-06	9.21e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—BCHE—breast cancer	6.38e-06	9.17e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CAV1—breast cancer	6.35e-06	9.12e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYP1B1—breast cancer	6.35e-06	9.12e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—SLC5A5—breast cancer	6.3e-06	9.06e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP3A4—breast cancer	6.3e-06	9.05e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KDR—breast cancer	6.28e-06	9.02e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ESR1—breast cancer	6.26e-06	8.99e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—HSP90AA1—breast cancer	6.22e-06	8.94e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP1B1—breast cancer	6.2e-06	8.9e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—FN1—breast cancer	6.18e-06	8.88e-05	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	6.16e-06	8.85e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ESR1—breast cancer	6.12e-06	8.79e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NFKBIA—breast cancer	6.11e-06	8.77e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NQO1—breast cancer	6.09e-06	8.75e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—SLC2A1—breast cancer	6.09e-06	8.75e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—HSP90AA1—breast cancer	6.08e-06	8.73e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NCOA1—breast cancer	6.06e-06	8.7e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NOTCH1—breast cancer	6.05e-06	8.69e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—FN1—breast cancer	6.05e-06	8.69e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NFKBIA—breast cancer	5.97e-06	8.58e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—STK11—breast cancer	5.97e-06	8.57e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYP19A1—breast cancer	5.97e-06	8.57e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP3A4—breast cancer	5.94e-06	8.53e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CD—breast cancer	5.92e-06	8.5e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NOTCH1—breast cancer	5.92e-06	8.5e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CG—breast cancer	5.92e-06	8.5e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—APC—breast cancer	5.92e-06	8.5e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KIT—breast cancer	5.92e-06	8.5e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NCOA1—breast cancer	5.91e-06	8.49e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—EGF—breast cancer	5.85e-06	8.4e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ALB—breast cancer	5.84e-06	8.39e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP1B1—breast cancer	5.84e-06	8.39e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—STK11—breast cancer	5.82e-06	8.37e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP19A1—breast cancer	5.82e-06	8.37e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KIT—breast cancer	5.79e-06	8.31e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CG—breast cancer	5.79e-06	8.31e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—APC—breast cancer	5.79e-06	8.31e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—HSP90AA1—breast cancer	5.73e-06	8.22e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—EGF—breast cancer	5.72e-06	8.22e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—MAPK3—breast cancer	5.66e-06	8.14e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—breast cancer	5.6e-06	8.05e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—NOS3—breast cancer	5.59e-06	8.03e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NCOA1—breast cancer	5.57e-06	8e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—BRAF—breast cancer	5.56e-06	7.99e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—COMT—breast cancer	5.55e-06	7.97e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—MAPK3—breast cancer	5.54e-06	7.96e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTP1—breast cancer	5.52e-06	7.93e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP19A1—breast cancer	5.49e-06	7.88e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—STK11—breast cancer	5.49e-06	7.88e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—HMOX1—breast cancer	5.45e-06	7.82e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—BRAF—breast cancer	5.44e-06	7.81e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ITPR1—breast cancer	5.43e-06	7.8e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IGF1—breast cancer	5.42e-06	7.78e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—COMT—breast cancer	5.41e-06	7.78e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—AKT2—breast cancer	5.41e-06	7.77e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTP1—breast cancer	5.39e-06	7.74e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—EGFR—breast cancer	5.39e-06	7.74e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—HMOX1—breast cancer	5.32e-06	7.63e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ITPR1—breast cancer	5.3e-06	7.62e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IGF1—breast cancer	5.3e-06	7.61e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—AKT2—breast cancer	5.29e-06	7.6e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—EGFR—breast cancer	5.27e-06	7.57e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ABCB1—breast cancer	5.23e-06	7.51e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CD—breast cancer	5.2e-06	7.47e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CB—breast cancer	5.16e-06	7.41e-05	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PIK3CA—breast cancer	5.15e-06	7.4e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SERPINE1—breast cancer	5.14e-06	7.39e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—TYMS—breast cancer	5.13e-06	7.37e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PTGS2—breast cancer	5.11e-06	7.34e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—COMT—breast cancer	5.1e-06	7.33e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—KRAS—breast cancer	5.09e-06	7.31e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CD—breast cancer	5.09e-06	7.31e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTP1—breast cancer	5.08e-06	7.3e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NCOR1—breast cancer	5.07e-06	7.29e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PLA2G4A—breast cancer	5.07e-06	7.29e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTM1—breast cancer	5.07e-06	7.29e-05	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CA—breast cancer	5.04e-06	7.24e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SERPINE1—breast cancer	5.03e-06	7.23e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—TYMS—breast cancer	5.01e-06	7.2e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—HMOX1—breast cancer	5.01e-06	7.19e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ITPR1—breast cancer	5e-06	7.18e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—KRAS—breast cancer	4.98e-06	7.15e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PLA2G4A—breast cancer	4.95e-06	7.11e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTM1—breast cancer	4.95e-06	7.11e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NCOR1—breast cancer	4.95e-06	7.11e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NOS3—breast cancer	4.91e-06	7.05e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GPX1—breast cancer	4.86e-06	6.98e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYP1A1—breast cancer	4.81e-06	6.91e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ABCB1—breast cancer	4.81e-06	6.91e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NOS3—breast cancer	4.8e-06	6.9e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ERCC2—breast cancer	4.77e-06	6.85e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GPX1—breast cancer	4.74e-06	6.81e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—TYMS—breast cancer	4.72e-06	6.78e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP1A1—breast cancer	4.69e-06	6.74e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CA—breast cancer	4.68e-06	6.72e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NCOR1—breast cancer	4.67e-06	6.7e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PLA2G4A—breast cancer	4.67e-06	6.7e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTM1—breast cancer	4.67e-06	6.7e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MDM2—breast cancer	4.66e-06	6.69e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ERCC2—breast cancer	4.66e-06	6.69e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—RAF1—breast cancer	4.64e-06	6.67e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—RELA—breast cancer	4.62e-06	6.64e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ERBB2—breast cancer	4.59e-06	6.6e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CA—breast cancer	4.58e-06	6.57e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MDM2—breast cancer	4.56e-06	6.55e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—RAF1—breast cancer	4.54e-06	6.52e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CB—breast cancer	4.53e-06	6.51e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MTOR—breast cancer	4.53e-06	6.51e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—RELA—breast cancer	4.52e-06	6.49e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ERBB2—breast cancer	4.49e-06	6.45e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—MTHFR—breast cancer	4.48e-06	6.44e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GPX1—breast cancer	4.47e-06	6.42e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PTEN—breast cancer	4.46e-06	6.4e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CB—breast cancer	4.43e-06	6.37e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MTOR—breast cancer	4.43e-06	6.37e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP1A1—breast cancer	4.42e-06	6.36e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ERCC2—breast cancer	4.39e-06	6.3e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—MTHFR—breast cancer	4.38e-06	6.29e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CXCL8—breast cancer	4.36e-06	6.26e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—HRAS—breast cancer	4.33e-06	6.22e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CXCL8—breast cancer	4.26e-06	6.12e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CDKN1B—breast cancer	4.25e-06	6.11e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—HRAS—breast cancer	4.23e-06	6.08e-05	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—AKT1—breast cancer	4.21e-06	6.04e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CASP3—breast cancer	4.17e-06	5.99e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IL2—breast cancer	4.16e-06	5.98e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CDKN1B—breast cancer	4.16e-06	5.98e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—IL6—breast cancer	4.14e-06	5.95e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CAV1—breast cancer	4.14e-06	5.94e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—MTHFR—breast cancer	4.12e-06	5.92e-05	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—AKT1—breast cancer	4.12e-06	5.91e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CASP3—breast cancer	4.08e-06	5.86e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IL2—breast cancer	4.07e-06	5.85e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CCND1—breast cancer	4.06e-06	5.83e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—IL6—breast cancer	4.05e-06	5.82e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—JUN—breast cancer	4.05e-06	5.82e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CAV1—breast cancer	4.04e-06	5.8e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CTNNB1—breast cancer	4.02e-06	5.77e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CCND1—breast cancer	3.97e-06	5.7e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—JUN—breast cancer	3.96e-06	5.69e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.95e-06	5.68e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MMP9—breast cancer	3.94e-06	5.66e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CTNNB1—breast cancer	3.93e-06	5.65e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CDKN1A—breast cancer	3.93e-06	5.64e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PTEN—breast cancer	3.92e-06	5.63e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MMP9—breast cancer	3.85e-06	5.54e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CDKN1A—breast cancer	3.84e-06	5.52e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MAPK8—breast cancer	3.83e-06	5.5e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PTEN—breast cancer	3.83e-06	5.5e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—AKT1—breast cancer	3.82e-06	5.49e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CAV1—breast cancer	3.8e-06	5.46e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CG—breast cancer	3.77e-06	5.41e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MAPK8—breast cancer	3.75e-06	5.38e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—AKT1—breast cancer	3.74e-06	5.37e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CG—breast cancer	3.68e-06	5.28e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SRC—breast cancer	3.63e-06	5.22e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SRC—breast cancer	3.55e-06	5.1e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—VEGFA—breast cancer	3.54e-06	5.08e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—STAT3—breast cancer	3.5e-06	5.03e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CG—breast cancer	3.47e-06	4.98e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—VEGFA—breast cancer	3.46e-06	4.97e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—STAT3—breast cancer	3.43e-06	4.92e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MAPK3—breast cancer	3.35e-06	4.81e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CD—breast cancer	3.31e-06	4.76e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MAPK3—breast cancer	3.27e-06	4.7e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ALB—breast cancer	3.27e-06	4.7e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MYC—breast cancer	3.25e-06	4.68e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TGFB1—breast cancer	3.25e-06	4.66e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CD—breast cancer	3.23e-06	4.64e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ALB—breast cancer	3.19e-06	4.58e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MYC—breast cancer	3.18e-06	4.57e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—EGFR—breast cancer	3.18e-06	4.57e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TGFB1—breast cancer	3.18e-06	4.56e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CA—breast cancer	3.14e-06	4.52e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NOS3—breast cancer	3.13e-06	4.49e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—EGFR—breast cancer	3.11e-06	4.47e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NOS3—breast cancer	3.05e-06	4.39e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CD—breast cancer	3.05e-06	4.38e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KRAS—breast cancer	3.01e-06	4.32e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ALB—breast cancer	3.01e-06	4.32e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KRAS—breast cancer	2.94e-06	4.23e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CB—breast cancer	2.89e-06	4.15e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NOS3—breast cancer	2.88e-06	4.13e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PTGS2—breast cancer	2.86e-06	4.11e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CB—breast cancer	2.82e-06	4.05e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTGS2—breast cancer	2.79e-06	4.01e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CA—breast cancer	2.76e-06	3.97e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CA—breast cancer	2.7e-06	3.88e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TP53—breast cancer	2.67e-06	3.84e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CB—breast cancer	2.66e-06	3.81e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTGS2—breast cancer	2.63e-06	3.78e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TP53—breast cancer	2.61e-06	3.76e-05	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—AKT1—breast cancer	2.57e-06	3.69e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HRAS—breast cancer	2.56e-06	3.67e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HRAS—breast cancer	2.5e-06	3.59e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PTEN—breast cancer	2.49e-06	3.58e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IL6—breast cancer	2.45e-06	3.51e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTEN—breast cancer	2.43e-06	3.5e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IL6—breast cancer	2.39e-06	3.44e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTEN—breast cancer	2.29e-06	3.3e-05	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—AKT1—breast cancer	2.26e-06	3.24e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—AKT1—breast cancer	2.21e-06	3.17e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CA—breast cancer	1.76e-06	2.53e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CA—breast cancer	1.72e-06	2.47e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CA—breast cancer	1.62e-06	2.33e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—AKT1—breast cancer	1.44e-06	2.07e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—AKT1—breast cancer	1.4e-06	2.02e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—AKT1—breast cancer	1.32e-06	1.9e-05	CbGpPWpGaD
